Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05200260 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 7 more changesShow less
    • Start date changed from estimate of Feb 2022 to Jul 13, 2022
    • Enrollment target: 207 to 220
    • Study sites: 1 to 9
    • Primary and study completion dates: Feb 2027 to Jun 2027
    • Interventions: Neoadjuvant chemotherapy (Procedure), PARP inhibitor (Drug), Primary debulking surgery (Procedure) to Bevacizumab (Drug), Neoadjuvant chemotherapy (Procedure), PARP inhibitor (Drug), Primary debulking surgery (Procedure)
    • Eligibility criteria expanded, about 4 words
    • Study description expanded, about 2 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer
Trial Details
NCT Number NCT05200260
Lead Sponsor Shanghai Gynecologic Oncology Group
Collaborators: Fudan University
Conditions
(from sponsor)		 Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Related terms Fallopian Tube Neoplasms, Ovarian Neoplasms
Enrollment 220 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov